Intellia Therapeutics Inc NTLA 深 滬
等待開盤 08-22 09:30:00 美东时间
10.125
-0.085
-0.83%
華盛通- 最 高10.245
- 今 開10.09
- 成交量 272.40万股
- 最 低 9.93
- 昨 收 10.21
- 總市值 10.53亿
- 52周最高 23.76
- 市盈率 靜 --
- 換手率 2.62%
- 52周最低 5.90
- 委 比 59.64%
- 總股本 1.04亿
- 歷史最高 202.73
- 量 比 0.56
- 振 幅 3.09%
- 歷史最低 5.90
- 每 手 1
- 風險率 4.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多投资者正获利了结？ARK创新ETF(ARKK.US)遭大规模赎回 “木头姐”伍德仍在逢低买入更多股票
由“木头姐”伍德管理的ARK创新ETF今年以来表现亮眼，但近期资金流向显示投资者可能在获利了结
08-20 06:00
ARK Investment buys 560K shares of Intellia Therapeutics
Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA). The stock has a Seeking Alpha quant rating of Hold, with the facto...
08-19 17:23
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock
Ark Invest, led by Cathie Wood, made significant trades on Monday, acquiring shares of Robinhood and Deere & Co. Other key trades also took place.
08-19 09:41
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews
In the latest quarter, 9 analysts provided ratings for Intellia Therapeutics (N...
08-12 02:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics reports strong progress in clinical trials for CRISPR-based therapies, including ahead-of-schedule enrollment in the MAGNITUDE trial for ATTR-CM and MAGNITUDE-2 study for ATTRv-PN. Lonvo-z's Phase 3 HAELO study is预计 to complete randomization by Q3 2025, and additional data from Phase 1/2 studies are expected in H2 2025. The company ended Q2 2025 with $630.5 million in cash, supporting operations into H1 2027. Collaboration r...
08-07 11:30
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Intellia Therapeutics will discuss its Q2 2025 financial results and operational highlights during a conference call on August 7, 2025, at 8 a.m. ET. U.S. callers should dial 1-833-316-0545, and international callers should dial 1-412-317-5726. A live webcast is available via the provided link. A replay will be accessible on the company’s website starting at 12 p.m. ET on August 7.
07-31 11:30
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
07-30 23:07
Insider Sales Shake Up Southern Co, Constellation, Intellia, US Bancorp, and Kohl’s
Insiders have been trading these 5 stocks: (($SO)), (($STZ)), (($NTLA)), (($USB...
07-26 21:01
